PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

46,361 stories, page 724 of 773

Advanced search
🇺🇸Industrynurabio.comTier 1 · Company source

Nura Bio Announces publication of “Structural and Mechanistic Regulation of the Prodegenerative NAD Hydrolase SARM1” in CELL REPORTS | Nura Bio™

Nura BioOriginal source
🌍Industryomniab.comTier 1 · Company source

CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application

OmniAbOriginal source
🇨🇦Mediainnovativemedicines.caTier 2 · Direct publisher

Meet the Experts: Dr. Doron Sagman

Innovative Medicines CanadaOriginal source
🇺🇰Industryorchard-tx.comTier 1 · Company source

Next-Generation Gene Therapy Manufacturing: A Key to Long-Term Growth and Sustainability

Orchard TherapeuticsOriginal source
🇧🇪Regulatoryfamhp.beTier 1 · Regulatory source

Coronavirus and the fight led by the FAMHP: the FAMHP carries out hundreds of controls and inspections to ensure the compliance and safety of medicines and health products

FAMHP (Belgium)Original source
🌍Mediasothema.comTier 2 · Direct publisher

Résultat du vote par résolution Assemblée Générale Ordinaire du 29 juin 2020

Sothema MoroccoOriginal source
🌍Mediasothema.comTier 2 · Direct publisher

Assemblée Générale Ordinaire des actionnaires, tenue le 29 Juin 2020

Sothema MoroccoOriginal source
🇨🇦Mediainnovativemedicines.caTier 2 · Direct publisher

The Hill Times,Letter to the Editor

Innovative Medicines CanadaOriginal source
🇧🇪Regulatoryfamhp.beTier 1 · Regulatory source

Coronavirus and the fight led by the FAMHP: solutions implemented by the FAMHP in the face of medical equipment shortages

FAMHP (Belgium)Original source
🇧🇷Researchfiocruz.brTier 2 · Direct publisher

Quanto tempo o coronavírus permanece ativo em diferentes superfícies?

Fiocruz NewsOriginal source
🌍Mediasothema.comTier 2 · Direct publisher

Formulaire de vote par correspondance à l’assemblée générale

Sothema MoroccoOriginal source
🌍Mediasothema.comTier 2 · Direct publisher

Conseil d’administration tenu le 26/05/2020

Sothema MoroccoOriginal source
🌍Mediasothema.comTier 2 · Direct publisher

Avis de convoncation de actionnaires

Sothema MoroccoOriginal source
🇩🇰Industryserviersymphogen.comTier 3 · Secondary coverage

Servier completes the acquisition of Symphogen

SymphogenOriginal source
🇨🇦Mediainnovativemedicines.caTier 2 · Direct publisher

Meet the experts: Dr. Alex Romanovschi

Innovative Medicines CanadaOriginal source
🇨🇦Mediainnovativemedicines.caTier 2 · Direct publisher

IMC local initiatives

Innovative Medicines CanadaOriginal source
🇬🇧Researchhdruk.ac.ukTier 2 · Direct publisher

129096 2

Health Data Research UKOriginal source
🇬🇧Researchhdruk.ac.ukTier 2 · Direct publisher

129094 2

Health Data Research UKOriginal source
🇨🇦Mediainnovativemedicines.caTier 2 · Direct publisher

Meet the experts: Vatche Bartekian

Innovative Medicines CanadaOriginal source
🇨🇦Mediainnovativemedicines.caTier 2 · Direct publisher

Meet the experts: Dion Neame

Innovative Medicines CanadaOriginal source
🇩🇰Industryserviersymphogen.comTier 3 · Secondary coverage

Symphogen to pursue COVID-19 antibody therapy in a collaboration with Aarhus University

SymphogenOriginal source
🇨🇦Mediainnovativemedicines.caTier 2 · Direct publisher

IMC welcomes federal Industry Strategy Council and looks forward to helping promote innovation, economic inclusion and growth

Innovative Medicines CanadaOriginal source
🇧🇪Regulatoryfamhp.beTier 1 · Regulatory source

Coronavirus: new version of Belgian directive for management of clinical trials during coronavirus pandemic

FAMHP (Belgium)Original source
🌍Industryguerbet.comTier 1 · Company source

Guerbet high in the Gaïa Index for the 2nd year running

GuerbetOriginal source
🌍Industryguerbet.comTier 1 · Company source

Guerbet en bonne position dans le Gaïa Index 2019 pour la 2ème année consécutive

GuerbetOriginal source
🇬🇧Researchhdruk.ac.ukTier 2 · Direct publisher

MyEyeSite: creating a patient-owned repository of inherited retinal disease data

Health Data Research UKOriginal source
🇩🇰Industryserviersymphogen.comTier 3 · Secondary coverage

Servier underskriver endelig aftale om at erhverve Symphogen, en førende antistof discovery virksomhed, for at styrke Serviers kapacitet inden for antistoffer samt dets forskning og udvikling

SymphogenOriginal source
🇩🇰Industryserviersymphogen.comTier 3 · Secondary coverage

Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline

SymphogenOriginal source
🇺🇸Researchcidrap.umn.eduTier 2 · Direct publisher

News Scan for Apr 02, 2020

CIDRAPOriginal source
🇺🇸Researchcidrap.umn.eduTier 2 · Direct publisher

Stewardship / Resistance Scan for Apr 02, 2020

CIDRAPOriginal source
🇧🇪Regulatoryfamhp.beTier 1 · Regulatory source

Pilot project on simultaneous national scientific advice starts 1 February 2020

FAMHP (Belgium)Original source
🇺🇸CDMOnoramco.comTier 2 · Direct publisher

Meet us at DCAT Week

NoramcoOriginal source
🌍Industryan2therapeutics.comTier 1 · Company source

AN2 Therapeutics Launches with $12 Million in Series A

AN2 TherapeuticsOriginal source
🌍Industryemzorpharma.comTier 1 · Company source

Emzor Wellocracy Radio Show with Pharm Tosin Oguntoye

Emzor PharmaceuticalOriginal source
🌍Industryemzorpharma.comTier 1 · Company source

Emzor Wellocracy Radio Show with Pharm Funmbi Okoya

Emzor PharmaceuticalOriginal source
🌍Industryemzorpharma.comTier 1 · Company source

Emzor Wellocracy Radio Show with Pharm Kehinde Adepoju

Emzor PharmaceuticalOriginal source
🌍Industryemzorpharma.comTier 1 · Company source

Emzor Wellocracy Radio Show with Pharm Muyiwa Olagunju

Emzor PharmaceuticalOriginal source
🇺🇸Researchcidrap.umn.eduTier 2 · Direct publisher

Stewardship / Resistance Scan for Aug 30, 2019

CIDRAPOriginal source
🇺🇸CROflorencehc.comTier 2 · Direct publisher

Why Remote Clinical Trial Monitoring is the New Standard

Florence HealthcareOriginal source
🌍Industryir.cyclerion.comTier 1 · Company source

Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months

Cyclerion TherapeuticsOriginal source
🇺🇸CROflorencehc.comTier 2 · Direct publisher

Overcoming Four Common Challenges in Multicenter Research

Florence HealthcareOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma Appoints Noel Donnelly as CFO - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Huntington's Disease - CervoMed

CervoMedOriginal source
🇺🇸CROflorencehc.comTier 2 · Direct publisher

Integrating the eTMF and eISF: Why and Why Now?

Florence HealthcareOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma to Host KOL Breakfast Briefing on Potential of Neflamapimod in Alzheimer's Disease and Dementia with Lewy Bodies - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma to Present at Upcoming Investor Conferences in June - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma to Present at BIO CEO Investor Conference - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma Announces Clinical Study Presentations at the 11th Clinical Trials on Alzheimer's Disease Conference and Provides Update on Phase 2b Clinical Study Enrollment - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma Secures $20.5 Million in Series B Financing - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma Announces Publication of Positive Alzheimer's Disease Clinical Study Data with Neflamapimod - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma announces presentation of new mechanism of action data regarding neflamapimod (VX-745) at Alzheimer's Association International Conference (AAIC) - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma announces presentation of new positive clinical data with neflamapimod (VX-745) at Alzheimer's Association International Conference (AAIC) - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer's Disease - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimer's disease and ischemic stroke recovery - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor - CervoMed

CervoMedOriginal source
🌍Industrycervomed.comTier 1 · Company source

EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) - CervoMed

CervoMedOriginal source
🇺🇸CROflorencehc.comTier 2 · Direct publisher

Technology in Multicenter Clinical Trials

Florence HealthcareOriginal source